Now that patients with metastatic castration-resistant prostate cancer have multiple therapeutic options, the question naturally arises as to how these therapies should be sequenced. The genitourinary group at Johns Hopkins has attempted to answer this question by investigating abiraterone and enzalutamide sequencing information in their database.
